Baxter renal replacement
This article was originally published in The Gray Sheet
Promotion of 30-year Baxter veteran Carlos de Salto to division president marks most recent move to revitalize business, as former Renal President Al Heller resigns to become a life sciences advisor to One Equity Partners. In 2002, Baxter initiated divestiture of the majority of its renal dialysis services, in favor of strengthening peritoneal and home dialysis offerings (1"The Gray Sheet" Dec. 9, 2002, p. 19)...
You may also be interested in...
Baxter International aims to expand its peritoneal and hemodialysis product offerings, particularly in the home setting, following a planned divestiture of the majority of its renal dialysis services
Officials from the US Food and Drug Administration cited their reasons for refusing to review new applications for companies with unresolved data integrity failures.
However, Vaccinex sees possible efficacy for SEMA4D inhibition in later-stage Huntington’s as well as Alzheimer’s disease. Pepinemab is also being studied with Keytruda in head-and-neck cancer.